Dengue Fever Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Pages: 203 Published: December 30, 2021 Report Code: GMDGDHC13191IDB

Dengue is a mosquito-borne infectious disease caused by the dengue virus. Symptoms include a high fever, headaches, joint and muscle pain, vomiting, and a rash. In some cases, dengue turns into dengue hemorrhagic fever, which causes bleeding from the nose, gums, or under the skin. It can also become dengue shock syndrome, which causes massive bleeding and shock. Treatment includes the use of analgesics, fluid replacement therapy, and a healthy lifestyle.

The Dengue Fever drugs in development market research report provide comprehensive information on the therapeutics under development for Dengue Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dengue Fever and features dormant and discontinued projects.

What are the key targets in the Dengue Fever pipeline products market?

The key targets in the Dengue Fever pipeline products market are Envelope Protein, Nonstructural Protein 4B, Nonstructural Protein 5, Premembrane Protein, Serine Protease NS3, Toll Like Receptor 4, Aryl Hydrocarbon Receptor, Envelope Protein M, Fibroblast Growth Factor 1, Fibroblast Growth Factor 2, and others.

Dengue Fever Pipeline Products Analysis Market by Targets

Dengue Fever Pipeline Products Analysis Market by Targets

For more target insights, download a free report sample

What are the key mechanisms of action in the Dengue Fever pipeline products market?

The key mechanisms of action in the Dengue Fever pipeline products market are Nonstructural Protein 4B Inhibitor, Envelope Protein Inhibitor, Nonstructural Protein 5 Inhibitor, Serine Protease NS3 Inhibitor, Toll Like Receptor 4 Antagonist, Aryl Hydrocarbon Receptor Antagonist, Envelope Protein M Inhibitor, Fibroblast Growth Factor 1 Inhibitor, Fibroblast Growth Factor 2 Inhibitor, Flavivirin Inhibitor, and others.

Dengue Fever Pipeline Products Market Analysis by Mechanism of Actions

Dengue Fever Pipeline Products Market Analysis by Mechanism of Actions

For more mechanism of actions insights, download a free report sample

What are the key routes of administration in the Dengue Fever pipeline products market?

The key routes of administration in the Dengue Fever pipeline products market are subcutaneous, oral, intravenous, intradermal, intramuscular, parenteral, and transdermal.

Dengue Fever Pipeline Products Market Analysis by Routes of Administration

Dengue Fever Pipeline Products Market Analysis by Routes of Administration

For more routes of administration insights, download a free report sample

What are the key molecule types in the Dengue Fever pipeline products market?

The key molecule types in the Dengue Fever pipeline products market are small molecule, live attenuated vaccine, subunit vaccine, vaccine, monoclonal antibody, recombinant vector vaccine, DNA vaccine, antibody, antisense RNAi oligonucleotide, biologic, and others.

Dengue Fever Pipeline Products Market Analysis by Molecule Type

Dengue Fever Pipeline Products Market Analysis by Molecule Type

For more molecule type insights, download a free report sample

Which are the major companies in the Dengue Fever pipeline products market?

Some of the major companies in the Dengue Fever pipeline products market are BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, 60 Degrees Pharmaceuticals LLC, Abivax SA, Imutex Ltd, Inovio Pharmaceuticals Inc, Moleculin Biotech Inc, and Novartis AG.

Dengue Fever Pipeline Products Market Analysis by Companies

Dengue Fever Pipeline Products Market Analysis by Companies

To know more about major companies, download a free report sample

Market Report Scope

Key targets Envelope Protein, Nonstructural Protein 4B, Nonstructural Protein 5, Premembrane Protein, Serine Protease NS3, Toll Like Receptor 4, Aryl Hydrocarbon Receptor, Envelope Protein M, Fibroblast Growth Factor 1, Fibroblast Growth Factor 2, and Others
Key mechanism of action Nonstructural Protein 4B Inhibitor, Envelope Protein Inhibitor, Nonstructural Protein 5 Inhibitor, Serine Protease NS3 Inhibitor, Toll Like Receptor 4 Antagonist, Aryl Hydrocarbon Receptor Antagonist, Envelope Protein M Inhibitor, Fibroblast Growth Factor 1 Inhibitor, Fibroblast Growth Factor 2 Inhibitor, Flavivirin Inhibitor, and Others
Key routes of administration Subcutaneous, Oral, Intravenous, Intradermal, Intramuscular, Parenteral, and Transdermal
Key molecule type Small Molecule, Live Attenuated Vaccine, Subunit Vaccine, Vaccine, Monoclonal Antibody, Recombinant Vector Vaccine, DNA vaccine, Antibody, Antisense RNAi Oligonucleotide, Biologic, and Others
Major companies BioNet-Asia Co Ltd, Emergex Vaccines Holding Ltd, Johnson & Johnson, Takeda Pharmaceutical Co Ltd, 60 Degrees Pharmaceuticals LLC, Abivax SA, Imutex Ltd, Inovio Pharmaceuticals Inc, Moleculin Biotech Inc, and Novartis AG

Scope

  • The report provides a snapshot of the global therapeutic landscape of Dengue Fever
  • The report reviews pipeline therapeutics for Dengue Fever Hypogonadism by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Dengue Fever Hypogonadism therapeutics and enlists all their major and minor projects
  • The report assesses Dengue Fever Hypogonadism therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA), and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews the latest news related to pipeline therapeutics for Dengue Fever

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Dengue Fever
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and their most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Dengue Fever pipeline depth and focus on Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from the pipeline

Key Players

  • 60 Degrees Pharmaceuticals LLC

    Abhelix LLC

    Abivax SA

    AbViro LLC

    Atea Pharmaceuticals Inc

    Avida Biotech SL

    Biological Mimetics Inc

    BioNet-Asia Co Ltd

    Biotron Ltd

    Cadila Healthcare Ltd

    Cidara Therapeutics Inc

    Codagenix Inc

    CycloLab Cyclodextrin Research and Development Laboratory Ltd

    Emergex Vaccines Holding Ltd

    Ennaid Therapeutics LLC

    Etna Biotech Srl

    Excivion Ltd

    Exopharm Ltd

    Globavir Biosciences Inc

    Greffex Inc

    Hercules Pharmaceuticals BV

    HSRx Group

    ImmuneMed Inc

    Immunotope Inc

    Imutex Ltd

    Indian Immunologicals Ltd

    Inovio Pharmaceuticals Inc

    Integral Molecular Inc

    Island Pharmaceuticals

    Johnson & Johnson

    KinoPharma Inc

    KM Biologics Co Ltd

    Macrophage Therapeutics Inc

    Medigen Inc

    Moleculin Biotech Inc

    Najit Technologies Inc

    Novartis AG

    Orgenesis Inc

    Panacea Biotec Ltd

    Plex Pharmaceuticals Inc

    ProtInhi BV

    Riboscience LLC

    Seagull BioSolutions Pvt Ltd

    Serum Institute of India Pvt Ltd

    Shionogi & Co Ltd

    Sun Pharma Advanced Research Company Ltd

    Takeda Pharmaceutical Co Ltd

    TechnoVax Inc

    Theravectys SA

    Vir Biotechnology Inc

    Virocovax

    Visterra Inc

    VLP Therapeutics LLC

    Xenothera SAS

    Zucero Therapeutics Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dengue Fever – Overview

Dengue Fever – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Dengue Fever – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dengue Fever – Companies Involved in Therapeutics Development

(dengue + zika) (pentavalent) vaccine – Drug Profile

Dengue Fever – Dormant Projects

Dengue Fever – Discontinued Products

Dengue Fever – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Dengue Fever, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Dengue Fever – Dormant Projects, 2021

Dengue Fever – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Dengue Fever, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Top 10 Molecule Types, 2021

Number of Products by Stage and Top 10 Molecule Types, 2021

Frequently Asked Questions

$2000

Can be used by individual purchaser only

$6000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.